Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease

Journal of Neuroscience

Volumn 23, Issue 10, 2003, Pages 4081-4091

  Crocker, Stephen J ^a   Smith, Patrice D ^a   Jackson Lewis, Vernice ^c   Lamba, Wiplore R ^a   Hayley, Shawn P ^a   Grimm, Erich ^d   Callaghan, Steve M ^a   Slack, Ruth S ^a   Melloni, Edon ^e   Przedborski, Serge ^c   Robertson, George S ^d   Anisman, Hymie ^f   Merali, Zul ^b   Park, David S ^a,g  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Merck Frosst and Company Canada Inc ^*  (United States)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^e UNIVERSITY OF GENOA   (Italy)

^f CARLETON UNIVERSITY   (Canada)

^g NONE   (Canada)

Author keywords

Adenovirus; Behavior; Dopamine; FosB; L Dopa; Neurotensin; Protease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPRAZOLAM; AMANTADINE; AMITRIPTYLINE; ANTIPARKINSON AGENT; BROMOCRIPTINE MESILATE; CALPAIN; CALPASTATIN; CARBIDOPA PLUS LEVODOPA; DICLOXACILLIN; DIGOXIN; DOCUSATE CALCIUM; ENALAPRIL MALEATE; FENTANYL; FUROSEMIDE; IBUPROFEN; LEVODOPA; LORAZEPAM; MORPHINE; OLANZAPINE; OXYBUTYNIN; PREDNISONE; PSEUDOMONIC ACID; RANITIDINE; SALICYLIC ACID; SELEGILINE; SULFACETAMIDE; TRIAZOLAM; UNINDEXED DRUG; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; CALCIUM; CALCIUM BINDING PROTEIN; CALPAIN INHIBITOR III; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDE; PROTEIN C FOS; TYROSINE 3 MONOOXYGENASE;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM; AGED; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOIMMUNOASSAY; STRIATONIGRAL DEGENERATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOVIRIDAE; AGED; AGED, 80 AND OVER; ANIMALS; BEHAVIOR, ANIMAL; CALCIUM; CALCIUM-BINDING PROTEINS; CALPAIN; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-FOS; RADIOIMMUNOASSAY; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0038380524     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-10-04081.2003     Document Type: Article

References (100)

1. Abarca J, Gysling K, Roth RH, Bustos G (1995) Changes in extracellular levels of glutamate and aspartate in rat substantia nigra induced by dopamine receptor ligands: in vivo microdialysis studies. Neurochem Res 20:159-169.
2. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247.
3. Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6:461-474.
4. Arthur JSC, Elce JS, Hegadorn C, Williams K, Greer PA (2000) Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol 20:4474-4481.
5. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-334.
6. Binder EB, Kinkead B, Owens MJ, Kilts CD, Nemeroff CB (2001) Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neurosci 21:601-608.
7. Bjorklund A, Lindvall O (1975) Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 83:531-537.
8. Carafoli E, Molinari M (1998) Calpain: a protease in search ofa function? Biochem Biophys Res Commun 247:193-203.
9. Cassarino DS, Parks JK, Parker Jr WD, Bennett Jr JP (1999) The parkinsonian neurotoxin MPP + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453:49-62.
10. Chen TS, Koutsilieri E, Rausch WD (1995) MPP+ selectively affects calcium homeostasis in mesencephalic cell cultures from embryonal C57/B16 mice. J Neural Transm Gen Sect 100:153-163.
11. Cheramy A, Leviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289:537-542.
12. Collier TJ, Sortwell CE, Elsworth JD, Taylor JR, Roth RH, Sladek Jr JR, Redmond Jr DE (2002) Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease. J Comp Neurol 442:320-330.
13. Crocker AD (1997) The regulation of motor control: an evaluation of the role of dopamine receptors in the substantia nigra. Rev Neurosci 8:55-76.
14. Crocker SJ, Morelli M, Wigle N, Nakabeppu Y, Robertson GS (1998) D1 receptor-related priming is attenuated by antisense-mediated "knock-down" of fosB expression. Brain Res Mol Brain Res 53:69-77.
15. Crocker SJ, Lamba WR, Smith PD, Callaghan SM, Slack RS, Anisman H, Park DS (2001a) c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci USA 98:13385-13390.
16. Crocker SJ, Wigle N, Liston P, Thomspon CS, Lee CJ, Xu DG, Roy S, Nicholson DW, Park DS, MacKenzie AE, Korneluk RG, Robertson GS (2001b) NAIP protects nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease: Eur J Neurosci 14:391-400.
17. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448.
18. De Tullio R, Sparatore B, Salamino F, Melloni E, Pontremoli S (1998) Rat brain contains multiple mRNAs for calpastatin. FEBS Lett 422:113-117.
19. Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of delta-FosB-like protein(s) in both rodent and primate striatum. Eur J Neurosci 8:365-381.
20. Eberhardt O, Coelin RV, Kugler S, Lindeneau J, Rathke-Hartlieb S, Gerhardt E, Haid S, Isenman S, Gravel C, Srinivasen A, Bahr M, Weller M, Dichgans J, Schulz JB (2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 20:9126-9134.
21. Emori Y, Kawasaki H, Imajoh S, Imajoh K, Suzuki K (1987) Endogenous inhibitor for calcium-dependent cysteine protease contains four internal repeats that could be responsible for its multiple reactive sites. Proc Natl Acad Sci USA 84:3590-3594.
22. Fernandez A, Jenner P, Marsden CD, De Ceballos ML (1995) Characterization of neurotensin-like immunoreactivity in human basal ganglia: increased neurotensin levels in substantia nigra in Parkinson's disease. Peptides 16:339-346.
23. Ford APDW, Marsden CA (1990) In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and d-Trpll-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat. Brain Res 53:243-250.
24. Forsythe P, Befus AD (2003) Inhibition of calpains is a component of nitric oxide-induced induced down-regulation of human mast cell adhesion. J Immunol 170:287-293.
25. Fox SH, Brotchie JM (2000) 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord 15:1064-1069.
26. Fox SH, Moser B, Brotchie JM (1998) Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxy-dopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151:35-49.
27. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Toronto: Academic.
28. 2+ release from mitochondria. FEBS Lett 198:99-102.
29. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999) Role of serotonin in the paradoxical calming effect of psycho-stimulants on hyperactivity. Science 283:397-401.
30. Gonen H, Shkedy D, Barnoy S, Kosower NS, Ciechanover A (1997) On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett 406:17-22.
31. Goto K, Iwamoto T, Kondo H (1994) Localization of mRNAs for calpain and calpastatin in the adult rat brain by in situ hybridization histochemistry. Brain Res Mol Brain Res 23:40-46.
32. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
33. Greenamyre JT, Sherer TB, Betarbet R, Panov AV (2001) Complex I and Parkinson's disease. IUBMB Life 52:135-141.
34. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML (1997) Construction of adenovirus vectors through Cre-lox recombination. J Virol 71:1842-1849.
35. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death ofdopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97:2875-2880.
36. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC (2001) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease but pathway inhibition results in neuronal necrosis. J Neurosci 21:2247-2255.
37. Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H (1999) Sensitization to the effects of tumor necrosis factor-α: neuroendocrine, central mono-amine, and behavioral variations. J Neurosci 19:5654-5665.
38. HeikkiIa RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469.
39. Hirai S, Kawasaki H, Yaniv M, Suzuki K (1991) Degradation oftranscription factors, c-Jun and c-Fos, by calpain. FEBS Lett 287:57-61.
40. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
41. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997) Neuronal vulnerability in Parkinson's disease. J Neural Transm [Suppl] 50:79-88.
42. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity, Proc Natl Acad Sci USA 82:2173-2177.
43. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13 [Suppl 1]:24-34.
44. Kass GE, Wright JM, Nicotera P, Orrenius S (1988) The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch Biochem Biophys 260:789 -797.
45. Kelly E, Jenner P, Marsden CD (1987) Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats. J Pharm Pharmacol 39:196-202.
46. Lapchak PA, Miller PJ, Collins F, Jiao S (1997) Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 78:61-72.
47. Lavoie B, Parent A (1991) Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. NeuroReport 2:601-604.
48. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neuro-toxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-364.
49. Li J, Grynspan F, Berman S, Nixon R, Bursztajn S (1996) Regional Differences in gene expression for calcium activated neutral proteases (calpains) and their endogenous inhibitor calpastatin in mouse brain and spinal cord. J Neurobiol 30:177-191.
50. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403-1409.
51. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 96:5774-5779.
52. Markgraf CG, Velayo NL, Johnson MP, McCarthy DR, Medhi S, Koehl JR, Chmielewski PA, Linnik MD (1998) Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 29:152-158.
53. Martorana A, Fusco FR, Picconi B, Massa R, Bernardi G, Sancesario G (2001) Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons. Synapse 41:360-362.
54. Mattson MP, LaFeria FM, Chan SL, Leissring MA, Shepel PN, Geiger JD (2000) Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 23:222-229.
55. Matuszewich L, Yamamoto BK (1999) Modulation of GABA release by dopamine in the substantia nigra. Synapse 32:29-36.
56. McMahon A, Wong BS, Iacopino AM, Ng MC, Chi S, German DC (1998) Calbindin-D28k buffers intracellular calcium and promotes resistance to degeneration in PC12 cells. Brain Res Mol Brain Res 54:56-63.
57. Melloni E, De Tullio R, Averna M, Tedesco I, Salamino F, Sparatore B, Pontremoli S (1998) Properties of calpastatin forms in rat brain. FEBS Lett 431:55-58.
58. Merali Z, Piggins H (1990) Effects ofdopamine D1 and D2 receptor agonists and antagonists on bombesin-induced behaviours. Eur J Pharmacol 191:281-293.
59. Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, Shimo-Nakanishi Y, Urabe T, Yamada M, Tamayose K, Shimada T, Miura M, Mizuno Y (2001) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 98:10918-10923.
60. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73:979-987.
61. Nakamura K, Bindokas VP, Marks JD, Wright DA, Frim DM, Miller RJ, Kang UJ (2000) The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 58:271-278.
62. Nestler EJ, Kelz MB, Chen J (1999) DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Res 835:10-17.
63. Palkovits M, Brownstein MJ (1988) Maps and guide to microdissection of the rat brain. New York: Elsevier.
64. Paschen W, Frandsen A (2001) Endoplasmic reticulum dysfunction - a common denominator for cell injury in acute and degenerative diseases of the brain? J Neurochem 79:719-725.
65. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neuro degeneration. Nature 402:615-622.
66. Perez-Otano I, Mandelzys A, Morgan JI (1998) MPTP-parkinsonism is accompanied by persistent expression of a delta- FosB- like protein in dopaminergic pathways. Brain Res Mol Brain Res 53:41-52.
67. Przedborski S, Jackson-Lewis V (2000) ROS and Parkinson's disease: a view to a kill. In: Free radicals in brain pathophysiology (Poli G, Cadenas E, Packer L, eds), pp 273-290. New York: Marcel Dekker.
68. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93:4565-4571.
69. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.J Neurochem 76:1265-1274.
70. Przedborski S, Jackson-Lewis V, Vila M, Wu du C, Teismann P, Tieu K, Choi DK,Cohen O (2003) Free radical and nitric oxide toxicity in Parkinson's disease. Adv Neurol 91:83-94.
71. Radke JM, Owens MJ, Ritchie JC, Nemeroff CB (1998) Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc Natl Acad Sci USA 95:11462-11464.
72. Ridoux V, Robert JJ, Zhang X, Perricaudet M, Mallet J, La Gal La Salle G (1994) Adenoviral vectors as functional retrograde neuronal tracers. Brain Res 648:171-175.
73. Roberts-Lewis JM, Savage MJ, Marcy VR, Pinsker LR, Siman R (1994) Immunolocalization of calpain 1 -mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci 14:3934-3944.
74. Robertson GS, Robertson HA (1988) Evidence that the substantia nigra is a site of action for L-DOPA. Neurosci Lett 89:204-208.
75. Robertson GS, Robertson HA (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.J Neurosci 9:3326-3331.
76. Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium - activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90:2628-2632.
77. Saporito MS, Brown EM, Miller MS, Carswell S (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 288:421-427.
78. Sato K, Kawashima S (2001) Calpain function in the modulation of signaltransduction molecules. Biol Chem 382:743-751.
79. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269.
80. Schimpff RM, Avard C, Fenelon G, Lhiaubet AM, Tenneze L, Vidailhet M, Rostene W (2001) Increased plasma neurotensin concentrations in patients with Parkinson's disease.'J Neurol Neurosurg Psychiatry 70:784-786.
81. Schulz JB, Matthews RT, Beal MF (1995) Role of nitric oxide in neurode-generative diseases. Curr Opin Neurol 8:480-486.
82. Sedelis M, Schwarting RK, Huston JP. (200 1) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125.
83. Sheehan JP, Swerdlow RH, Parker WD, Miller SW, Davis RE, Tuttle JB (1997) Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J Neurochem 68:1221-1233.
84. Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP Jr, Tuttle JB (2001) Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Res 891:94-105.
85. Shiraha H, Glading A, Chou J, Jia Z, Wells A (2002) Activation ofm-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol 22:2716-2727.
86. Sorimachi H, Ishiura S, Suzuki K (1997) Structure and physiological function of calpains. Biochem J 328:721-732.
87. Suzuki K, Saido TC, Hirai S (1992) Modulation of cellular signals by calpain. Ann NY Acad Sci 674:218-227.
88. Tatton NA, Kish SJ (1997) In situ detection ofapoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
89. Thibaut F, Faucheux BA, Marquez J, Villares J, Menard JF, Agid Y, Hirsch EC (1995) Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 692:233-243.
90. Trimmer PA, Smith TS, Jung AB, Bennett JP Jr (1996) Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5:233-239.
91. Tseng JL, Baetge EE, Zurn AD, Aebischer P (1997) GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J Neurosci 17:325-333.
92. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Kors-meyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neuro-degeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98:2837-2842.
93. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK (2001) Caspase-9 activation results in down-stream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 21:9519-9528.
94. Wang KKW, Yuen P-W (1994) Calpain inhibition: an overview ofits therapeutic potential. Trends Pharmacol 15:412-419.
95. Wittmann M, Marino MJ, Conn PJ (2002) Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther 302:433-441.
96. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz JB (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:10433-10438.
97. Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 526:303-307.
98. Yamashima T, Kohda Y, Tsuchiya K, Ueno T, Yamashita J, Yoshioka T, Kominami E (1998) Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuro-protection based on "calpain-cathepsin hypothesis". Eur J Neurosci 10:1723-1733.
99. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney Jr JB, Hyman BT, Beal MF (1998) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 18:8145-8152.
100. Zimmerman UJ, Boring L, Pak JH, Mukerjee N, Wang KK (2000) Thecalpain small subunit gene is essential: its inactivation results in embryonic lethality. IUBMB Life 50:63-68.